Today: 27 April 2026
Stanley Black & Decker Stock Rises as $500 Million Buyback Puts Cash Returns Back in Focus
27 April 2026
2 mins read

Stanley Black & Decker Stock Rises as $500 Million Buyback Puts Cash Returns Back in Focus

New Britain, Connecticut, April 27, 2026, 17:05 EDT

  • Stanley Black & Decker stock jumped Monday, with the tool maker unveiling a fresh $500 million share repurchase program.
  • Just two days out from first-quarter earnings, investors are zeroed in on tariff expenses, demand for tools, and where the cash flow stands.
  • The quarterly dividend stays put at $0.83 per share.

Stanley Black & Decker jumped roughly 4% Monday. The DeWalt and Craftsman parent signed off on a $500 million buyback plan and kept its quarterly dividend intact, offering investors another cue on capital returns ahead of earnings later this week. Shares were last changing hands at $79.86, up $3.22, with more than 2.6 million traded.

Timing is key here. Stanley’s first-quarter earnings land Wednesday, with investors eager to see whether price hikes, cost reductions, and tariff strategies are enough as power tool demand stays patchy. The board set a dividend of $0.83 a share, payable June 23 to shareholders registered by June 8.

On April 23, the board signed off on the new buyback plan, which will stay in effect for 36 months. Stanley simultaneously scrapped its previous program that had allowed for the repurchase of up to 20 million shares—none of which had been bought back.

Buybacks can boost earnings per share because the number of shares drops, but they don’t address demand issues. The company said it’s considering open market purchases, private transactions, or accelerated repurchases—funded by cash, short-term loans, or other resources. There’s no commitment to actually repurchase any shares.

Stanley’s new capital-return plan lands after a rough period for tool manufacturers. Back in February, Reuters said the company projected 2026 adjusted earnings between $4.90 and $5.70 per share—midpoint’s underneath the consensus from LSEG analysts—as softer demand and higher prices from tariffs dragged on sales.

Stanley has leaned on price hikes, tweaks to its supply chain, and cost-cutting to combat mounting headwinds. The fourth-quarter update showed net sales slipping 1% to $3.7 billion, with adjusted earnings per share at $1.41. For all of 2025, sales came in at $15.1 billion, off 2%.

Back in February, Chief Executive Chris Nelson pointed to margin improvements and better cash flow, even as the company faced tough conditions. He also cautioned that 2026 might shape up to be “another uncertain, dynamic year.” Stanley Black Decker

Tariffs are still in play. On April 20, Stanley said the updated Section 232 tariffs—those are the national-security-related trade duties—shouldn’t materially alter its 2026 outlook. More specifics will come during the April 29 earnings call.

Shares also reacted after Stanley wrapped up the sale of its Consolidated Aerospace Manufacturing unit to Howmet Aerospace earlier this month. The transaction, which Stanley had said would generate $1.8 billion in cash, is expected to boost the company’s financial flexibility. Management now has a bit more latitude to juggle debt paydown, dividends, and stock buybacks.

Industrial tool makers are grappling with similar issues: just how much price can be passed along to consumers and contractors, and whether demand picks up in housing, repair, and retail channels. Snap-on, Illinois Tool Works, and Techtronic Industries all have stakes in the broader tools and industrial gear space. Stanley, however, leans heavily on its DeWalt, Craftsman, and Black+Decker lines, making it particularly sensitive to shifts in tools and outdoor spending.

There’s a risk here: the buyback could end up acting as a shield rather than a strategic move. Should North American retail demand remain sluggish—or if rising tariffs and input expenses push the company to raise prices again—Stanley might be forced to weigh holding onto cash against rewarding shareholders. The company has already noted that it can pause or halt repurchases anytime, citing liquidity, share price, market conditions, and legal rules as factors.

Investors at least have clarity on shareholder returns for now. The tougher challenge lands Wednesday: Stanley must prove its margins and cash flow can hold up, even as the market remains a tough environment for tool makers.

Stock Market Today

  • SQM Valuation Under Scrutiny Amid New Lithium Oversupply Concerns
    April 27, 2026, 5:29 PM EDT. Sociedad Química y Minera de Chile (SQM) faces fresh lithium market oversupply concerns raised by Rothschild & Co Redburn research. Despite recent share price gains-up 7.36% in 30 days and 27.33% year-to-date-SQM trades at $88.79 against a perceived fair value of $75.33, implying a 17.9% overvaluation. Expansion plans in Australia and Chile, including projects like Salar Futuro, bolster long-term growth potential, but lithium price volatility and Chilean regulatory risks cloud the outlook. Conflicting discounted cash flow (DCF) models add uncertainty, with one suggesting an intrinsic value of $113.84, highlighting divergent investor perspectives on SQM's earnings and growth prospects in a shifting lithium market.

Latest article

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

27 April 2026
Oruka Therapeutics reported its experimental psoriasis drug ORKA-001 achieved complete skin clearance in 63.5% of patients at 16 weeks. Shares jumped 10.5% to $76.39 before the company launched a $500 million public offering. No serious adverse events were reported in the trial. ORKA-001 is being developed as a long-acting injectable, with annual dosing possible.
Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

Why Rambus Stock Fell Even as AI Memory Sales Jumped in Q1

27 April 2026
Rambus shares fell 10.8% to $141.31 Monday after reporting first-quarter revenue of $180.2 million and net income of $59.9 million. Product revenue rose 15% to $88 million, driven by AI data-center demand. The company forecast higher second-quarter product revenue but said results depend on customer deals. Rambus recently launched a new server memory module aimed at AI systems.
Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million
Previous Story

Oruka Therapeutics Stock Surges After Psoriasis Drug Data as Biotech Seeks $500 Million

Go toTop